About 2-Hydroxyacid oxidase 1
2-Hydroxyacid oxidase 1 (HAO1) is a protein
from Homo sapiens identified by UniProt accession
Q9UJM8, 370 residues long.
MolForge cross-references it against 0 known binders and
88 disease associations.
Target properties
| Protein name | 2-Hydroxyacid oxidase 1 |
| UniProt accession | Q9UJM8 |
| Gene | HAO1 |
| Organism | Homo sapiens |
| Length | 370 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (88)
Diseases linked to this target (Open Targets).
- calcium oxalate urolithiasis · score 0.52
- nephrolithiasis susceptibility caused by SLC26A1 · score 0.52
- primary hyperoxaluria type 1 · score 0.48
- primary hyperoxaluria · score 0.47
- colorectal cancer · score 0.42
- traffic air pollution measurement · score 0.33
- protein measurement · score 0.33
- body height · score 0.31
- colorectal adenoma · score 0.27
- ossification of the posterior longitudinal ligament of the spine · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UJM8-F1 | alphafold | PREDICTED | 94.54 | — |
Amino-acid sequence (370 residues)
MLPRLICIND YEQHAKSVLP KSIYDYYRSG ANDEETLADN IAAFSRWKLY PRMLRNVAET DLSTSVLGQR VSMPICVGAT AMQRMAHVDG ELATVRACQS LGTGMMLSSW ATSSIEEVAE AGPEALRWLQ LYIYKDREVT KKLVRQAEKM GYKAIFVTVD TPYLGNRLDD VRNRFKLPPQ LRMKNFETST LSFSPEENFG DDSGLAAYVA KAIDPSISWE DIKWLRRLTS LPIVAKGILR GDDAREAVKH GLNGILVSNH GARQLDGVPA TIDVLPEIVE AVEGKVEVFL DGGVRKGTDV LKALALGAKA VFVGRPIVWG LAFQGEKGVQ DVLEILKEEF RLAMALSGCQ NVKVIDKTLV RKNPLAVSKI
Explore 2-Hydroxyacid oxidase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets